Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Rafael Holdings, Inc.

Real Estate US RFL

1.35USD
-0.02(1.46%)

Last update at 2026-06-03T20:00:00Z

Day Range

1.301.36
LowHigh

52 Week Range

1.442.52
LowHigh

Fundamentals

  • Previous Close 1.37
  • Market Cap44.85M
  • Volume50790
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.30350M
  • Revenue TTM0.28M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.41M
  • Diluted EPS TTM-0.29

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Income before tax -8.74500M -139.97200M -25.13100M -6.91600M -4.94300M
Minority interest 0.34M 17.72M 14.42M -0.33800M 13.78M
Net income -1.87600M -124.65800M -25.14900M -6.94500M -4.92400M
Selling general administrative 8.93M 16.98M 20.42M 9.12M 8.82M
Selling and marketing expenses - - - - -
Gross profit 0.28M 0.41M 3.97M 4.91M 4.93M
Reconciled depreciation 0.08M 0.07M 1.46M 1.87M 1.78M
Ebit -17.59200M 19.17M -29.81200M -8.46500M -6.69600M
Ebitda -17.51400M 19.24M -19.11000M -6.54700M -6.20100M
Depreciation and amortization 0.08M 0.07M 10.70M 1.92M 0.49M
Non operating income net other - - - 0.19M 0.38M
Operating income -15.04300M 19.17M -29.81200M -8.46500M -6.69600M
Other operating expenses 15.32M 60.89M 26.78M 13.38M 11.63M
Interest expense 0.00000M 0.00600M 0.10M 0.08M 3.27M
Tax provision -0.25500M 0.00000M 0.02M 0.03M -0.01900M
Interest income 3.25M 0.20M 4.66M 1.65M 1.75M
Net interest income 3.25M 0.20M -0.10200M -0.03200M 0.47M
Extraordinary items 6.48M -1.83000M -1.70500M 0.00000M 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -0.25500M -15.31400M 0.02M 0.03M -0.01900M
Total revenue 0.28M 0.41M 3.97M 4.91M 4.93M
Total operating expenses 15.32M 60.89M 26.78M 13.38M 11.63M
Cost of revenue - - - - 0.00000M
Total other income expense net 6.30M -159.14000M 4.68M 1.55M 1.75M
Discontinued operations - -1.83000M -1.70500M -1.70500M -1.70500M
Net income from continuing ops -8.69300M -140.54700M -24.76600M -6.95400M -4.92400M
Net income applicable to common shares -1.87600M -124.65800M -24.54400M -10.41500M -4.69300M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Total assets 98.83M 118.32M 154.06M 136.35M 142.14M
Intangible assets 1.57M 1.57M 1.57M 1.57M 1.57M
Earning assets - - - - -
Other current assets 0.91M 44.81M 1.07M 0.27M 0.51M
Total liab 2.20M 21.11M 17.35M 5.82M 17.38M
Total stockholder equity 100.29M 100.52M 122.29M 116.80M 110.98M
Deferred long term liab - 1.57M 1.57M 1.57M 1.57M
Other current liab 1.81M 5.46M 0.25M 0.12M 0.63M
Common stock 0.24M 0.24M 0.18M 0.16M 0.14M
Capital stock 0.24M 0.24M 0.18M 0.16M 0.14M
Retained earnings -167.33300M -165.45700M -40.79900M -16.25500M -5.84000M
Other liab - 0.09M 0.05M 0.09M 1.01M
Good will - - - - 0.00000M
Other assets 0.00900M 2.96M 10.59M 3.16M 3.01M
Cash 21.50M 26.54M 7.85M 6.21M 12.02M
Cash and equivalents 21.50M 26.54M 7.85M 6.21M 12.02M
Total current liabilities 2.15M 21.03M 17.30M 5.73M 1.43M
Current deferred revenue - - 1.36M 3.50M -
Net debt -21.49800M -11.53700M 6.67M -6.20600M 2.92M
Short term debt 0.00000M 15.00M 14.53M 1.19M 0.00000M
Short long term debt - 15.00M 14.53M - 0.00000M
Short long term debt total - 15.00M 14.53M 0.12M 14.95M
Other stockholder equity 264.01M 262.02M 159.14M 129.14M 112.90M
Property plant equipment 1.70M 1.77M 43.24M 44.43M 48.73M
Total current assets 82.94M 108.35M 14.76M 9.83M 13.26M
Long term investments 7.62M 0.48M 80.19M 70.02M 72.02M
Net tangible assets - 100.52M 122.29M 116.80M 110.98M
Short term investments 58.01M 36.70M 0.57M - 0.00000M
Net receivables 2.52M 0.30M 0.83M 0.39M 0.73M
Long term debt - - - 0.00000M 14.95M
Inventory - - 5.00M 2.97M 0.00000M
Accounts payable 0.33M 0.56M 1.16M 0.92M 0.80M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - 13.73M 13.78M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 3.37M 3.70M 3.77M 3.76M 3.78M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 0.18M 0.16M 0.14M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - -16.25500M -5.84000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 0.00900M 6.15M 1.52M 9.09M 6.54M
Deferred long term asset charges - - - - 0.02M
Non current assets total 15.89M 9.97M 139.29M 126.52M 128.88M
Capital lease obligations - - - - 0.00000M
Long term debt total 0.00000M 0.00000M 0.00000M 0.00000M 14.95M
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Investments 21.21M -36.80600M -8.17100M -1.03400M -30.83900M
Change to liabilities - 0.05M 0.16M 0.82M 1.94M
Total cashflows from investing activities 21.21M -63.79600M -8.17100M -1.03400M -31.23800M
Net borrowings - - 15.00M 15.00M 18.34M
Total cash from financing activities -15.21800M 103.86M 30.30M -0.09600M 30.89M
Change to operating activities - -0.13600M -0.99200M 0.35M 1.32M
Net income -2.21500M -140.54700M -24.76600M -10.75300M -4.92400M
Change in cash -5.03900M 13.68M 6.65M -5.81800M -3.77900M
Begin period cash flow 26.54M 12.85M 6.21M 12.02M 15.80M
End period cash flow 21.50M 26.54M 12.85M 6.21M 12.02M
Total cash from operating activities -10.88600M -26.07900M -15.60100M -4.66600M -3.13200M
Issuance of capital stock 0.00000M 110.17M 13.00M 0.00000M 7.78M
Depreciation 0.08M 0.07M 1.46M 1.87M 1.78M
Other cashflows from investing activities 21.21M -26.98800M -0.50000M -0.50000M -30.83900M
Dividends paid - - - - 0.00000M
Change to inventory - - -1.12800M 0.42M 1.32M
Change to account receivables -0.11700M 0.07M -0.16100M 0.09M -0.28500M
Sale purchase of stock 0.00000M 110.17M 15.07M 0.03M 0.86M
Other cashflows from financing activities -15.21800M -6.30300M 17.30M -0.09600M 22.25M
Change to netincome - 98.52M 8.44M 0.72M -0.26400M
Capital expenditures 51.68M 0.00200M 0.21M 0.53M 0.40M
Change receivables - - - 0.25M -0.56500M
Cash flows other operating - - - 2.38M -1.11800M
Exchange rate changes - - - -0.02200M -0.29800M
Cash and cash equivalents changes - - - -5.81800M -3.77900M
Change in working capital -0.09200M -0.01000M -0.98900M 1.15M 1.64M
Stock based compensation 2.19M -0.91700M 8.66M 3.00M -0.74300M
Other non cash items -11.78900M 115.32M 0.03M 0.05M -0.86800M
Free cash flow 40.79M -26.08100M -15.80700M -5.20000M -3.53100M

Peer Comparison

Sector: Real Estate Industry: Real Estate Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RFL
Rafael Holdings, Inc.		 -0.02 1.46% 1.35 - - 161.90 0.46 3.52 0.56
MSGNF
Man Sang International Limited		 - -% 0.0015 - - 844.75 3.95 3.76 -1.3608
CBRE
CBRE Group Inc Class A		 -1.83 1.43% 126.03 38.92 21.37 1.09 4.95 1.28 25.73
BEKE
Ke Holdings Inc		 -0.32 1.86% 16.91 42.90 16.92 0.33 2.33 1.66 24.07
VONOY
Vonovia SE ADR		 -0.38 3.14% 11.71 - 13.24 3.92 0.81 4.11 -3.0745

Reports Covered

Stock Research & News

View All

Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Rafael Holdings, Inc.

520 Broad Street, Newark, NJ, United States, 07102

Key Executives

Name Title Year Born
Mr. Howard S. Jonas Founder & Chairman 1956
Mr. William Conkling Chief Exec. Officer 1972
Mr. Patrick Fabbio M.B.A. CFO & Pres 1968
Ms. Barbara A. Ryan Investor Relations Officer 1960
Mr. David A. Polinsky Esq. Chief of Staff 1972
Mr. Gus Kodersha Chief Technical Operations Officer NA
Dr. Rick Ewing Head of Drug Discovery NA
Ms. Joyce J. Mason Esq. Corp. Sec. 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions